摘要
Stromal vascular fraction(SVF)therapy is a promising regenerative medicine strategy derived from adipose tissue,containing a heterogeneous mix of cells,including adipose-derived stem,endothelial,and immune cells.Despite its potential in treating conditions like osteoarthritis,chronic wounds,and myo-cardial ischemia,significant challenges impede its clinical translation.Key obstacles include biological variability in SVF composition,unclear mechanisms of action,regulatory ambiguities,and the technical difficulty of ensuring stan-dardized and scalable isolation methods.Furthermore,patient-specific factors,ethical concerns,and the need for comprehensive efficacy assessment complicate clinical application.Addressing these challenges requires advancements in technology,regulatory flexibility,interdisciplinary collaboration,and person-alized therapeutic approaches.Innovations such as automated isolation systems,advanced biomaterials,and CRISPR-based gene editing are potential solutions to improve the therapeutic reliability of SVF.A structured roadmap,including preclinical research,regulatory approval,and post-market surveillance,is proposed to advance SVF therapies from the laboratory to clinical practice.Future directions should focus on large-scale clinical trials,biomarker development,real-world evidence generation,and standardization of protocols to enhance the safety,efficacy,and accessibility of SVF,ultimately realizing its potential as a versatile therapeutic in regenerative medicine.
